Updates are available Correction dated 2026-02-10
Click to view Correction: https://doi.org/10.1038/s41467-026-69474-1
-
Authors
Dutta, Arghya https://orcid.org/0000-0003-2116-6475
Cristiani, Alberto https://orcid.org/0009-0004-8273-3386
Nikte, Siddhanta V. https://orcid.org/0000-0002-1553-3040
Eisert, Jonathan https://orcid.org/0009-0001-6850-5908
Matthess, Yves https://orcid.org/0000-0003-4040-1258
Markusic, Borna https://orcid.org/0009-0007-8302-812X
Tudose, Cosmin https://orcid.org/0000-0002-9314-9108
Becht, Chiara https://orcid.org/0009-0008-7991-5807
Cetin, Ronay
Shah, Varun Jayeshkumar
Mosler, Thorsten https://orcid.org/0000-0003-1800-2680
Husnjak, Koraljka
Dikic, Ivan https://orcid.org/0000-0001-8156-9511
Kaulich, Manuel https://orcid.org/0000-0002-9528-8822
Bhaskara, Ramachandra M. https://orcid.org/0000-0002-7742-0391
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (PROXIDRUGs project, InnoDATA-1.0 ID 03ZU1109KA and InnoDATA-2.0 ID 03ZU2109JA)
Deutsche Forschungsgemeinschaft (Project-ID 259130777-SFB1177)
Deutsche Forschungsgemeinschaft (Project-ID 259130777-SFB1177)
- License Information
-
More Information
Article History
Received: 11 March 2025
Accepted: 1 December 2025
First Online: 25 December 2025
Change Date: 10 February 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-026-69474-1
Competing interests
: R.M.B., M.K., K.H., and I.D. are head scientists at the Frankfurt Competence Center for Emerging Therapeutics (FCET), Goethe Center for (high) technology (Go4Tec), Goethe University, Frankfurt am Main, Germany. The remaining authors declare no competing interests. This manuscript reflects the views of the authors, and neither IMI nor the European Union, EFPIA, nor any associated partners are liable for any use that may be made of the information contained herein. I.D. is a founder/shareholder of Vivlion GmbH and a member of its scientific advisory board. I.D. is also a member of the scientific advisory board of the Boehringer Ingelheim Foundation, the expert committee (for international research leader grants) of the Novo Nordisk Foundation, and the advisory board of Cell and Molecular Cell. I.D. was a founder and consultant of Caraway Therapeutics Inc. M.K. is a co-founder, shareholder, and chief officer of Vivlion GmbH.
